EPA/DHA supplements: The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. Each capsule will contain 330mg EPA and 220mgDHA.
ALA supplements: The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. Daily dose will contain 3500mg ALA.
Placebo supplements: The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. One capsule will contain 550 mg of olive oil. The placebo will be matched to the supplement in appearance.
Study summary
Therefore, the aim of our project will be to assess the impact of omega-3 fatty acid on the neuromuscular system (muscle tensomyography- TMG), the composition and fluidity of erythrocyte cell membranes, the lipid profile and the antioxidant status of the blood.
Eligibility
Sex
MALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
\*\*Inclusion Criteria:\*\*
* Male participants aged 20-40 years.
* Apparently healthy individuals, as determined by medical history and self-reported health status.
* Physically active, engaging in regular physical activity at least 3 times per week for the previous 6 months.
* Following a mixed diet.
* Willingness to maintain habitual dietary and physical activity patterns throughout the study.
* Willingness to refrain from consuming dietary supplements other than those provided as part of the study.
\*\*Exclusion Criteria:\*\*
* Current use of dietary supplements within 4 weeks prior to enrollment.
* Following a low-carbohydrate, ketogenic, high-carbohydrate, vegetarian, or vegan diet.
* Presence of gastrointestinal disorders affecting nutrient absorption, including irritable bowel syndrome, inflammatory bowel disease, celiac disease, or other clinically significant gastrointestinal conditions.
* History of cardiovascular, metabolic, endocrine, hepatic, renal, neurological, or autoimmune diseases.
* Current use of medications known to affect lipid metabolism, inflammation, antioxidant status, or cognitive function.
* Known allergy or intolerance to study supplements or their ingredients.
* Participation in another clinical trial within the previous 3 months.
Primary outcome measure(s)
Omega 3 index — 4-weeks The Omega-3 Index (%) determines the content of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) relative to total fatty acids in erythrocyte membranes. It is expressed as a percentage and reflects long-term fatty acid intake.
Unit of Measure: %
Trial sites (1)
Facility
City
Region
Status
Academy of Physical Education in Katowice
Katowice
Poland
More The Jerzy Kukuczka Academy of Physical Education in Katowice trials in Poland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
